Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Davis

Showing results (141-150 of 505) with videos related to

Pageof 51
Sort By:
The British Journal of Nutrition|June 18, 2011
Don't disregard the essential distinction between PUFA speciesChristopher E Ramsden, Joseph R Hibbeln, Sharon F Majchrzak-Hong, et al.
Schizophrenia Bulletin|October 18, 2024
Clinician-Reported Negative Symptom Scales: A Systematic Review of Measurement PropertiesLucia Weigel, Sophia Wehr, Silvana Galderisi, et al.
Current Neuropharmacology|March 16, 2026
Alterations in GABAergic Interneurons, Neuroinflammation, and Epigenetics: Potential Targets for Therapeutic Strategies in SchizophreniaFrancesco Matrisciano, Olusola A Ajilore, John M Davis, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 21, 2026
Problem-, resources- and goals-oriented (PRoGO) approach in psychiatry: illustrated by the case of Ludwig II of BavariaStefan Leucht, John M Davis, Kerem Böge, et al.
Journal of Clinical Psychopharmacology|October 2, 2003
Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled: an open-label retrospective studyDavid S Janowsky, John E Kraus, Jarrett Barnhill, et al.
The Cochrane Database of Systematic Reviews|May 18, 2012
Maintenance treatment with antipsychotic drugs for schizophreniaStefan Leucht, Magdolna Tardy, Katja Komossa, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 9, 2007
Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffsStefan Leucht, John M Davis, Rolf R Engel, et al.
Schizophrenia Research|January 14, 2022
About the issue of including or excluding studies from China in systematic reviewsStefan Leucht, Chunbo Li, John M Davis, et al.
Schizophrenia Research. Cognition|July 23, 2024
Relationship of cognitive measures to mRNA levels in lymphocytes from patients with schizophrenia and controlsRobert C Smith, Henry Sershen, AnMei Chen, et al.
Mayo Clinic Proceedings|October 18, 2019
Evidence of Diagnostic and Treatment Delay in Seronegative Rheumatoid Arthritis: Missing the Window of OpportunityCaitrin M Coffey, Cynthia S Crowson, Elena Myasoedova, et al.
Pageof 51

Showing results (141-150 of 505) with videos related to

Sort By:
Pageof 51
The British Journal of Nutrition|June 18, 2011
Don't disregard the essential distinction between PUFA speciesChristopher E Ramsden, Joseph R Hibbeln, Sharon F Majchrzak-Hong, et al.
Schizophrenia Bulletin|October 18, 2024
Clinician-Reported Negative Symptom Scales: A Systematic Review of Measurement PropertiesLucia Weigel, Sophia Wehr, Silvana Galderisi, et al.
Current Neuropharmacology|March 16, 2026
Alterations in GABAergic Interneurons, Neuroinflammation, and Epigenetics: Potential Targets for Therapeutic Strategies in SchizophreniaFrancesco Matrisciano, Olusola A Ajilore, John M Davis, et al.
European Archives of Psychiatry and Clinical Neuroscience|January 21, 2026
Problem-, resources- and goals-oriented (PRoGO) approach in psychiatry: illustrated by the case of Ludwig II of BavariaStefan Leucht, John M Davis, Kerem Böge, et al.
Journal of Clinical Psychopharmacology|October 2, 2003
Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled: an open-label retrospective studyDavid S Janowsky, John E Kraus, Jarrett Barnhill, et al.
The Cochrane Database of Systematic Reviews|May 18, 2012
Maintenance treatment with antipsychotic drugs for schizophreniaStefan Leucht, Magdolna Tardy, Katja Komossa, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 9, 2007
Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffsStefan Leucht, John M Davis, Rolf R Engel, et al.
Schizophrenia Research|January 14, 2022
About the issue of including or excluding studies from China in systematic reviewsStefan Leucht, Chunbo Li, John M Davis, et al.
Schizophrenia Research. Cognition|July 23, 2024
Relationship of cognitive measures to mRNA levels in lymphocytes from patients with schizophrenia and controlsRobert C Smith, Henry Sershen, AnMei Chen, et al.
Mayo Clinic Proceedings|October 18, 2019
Evidence of Diagnostic and Treatment Delay in Seronegative Rheumatoid Arthritis: Missing the Window of OpportunityCaitrin M Coffey, Cynthia S Crowson, Elena Myasoedova, et al.
Pageof 51